• <Âé¶¹´«Ã½ÊÓÆµ> Case 30: Pancreatic Cystic Neoplasm

    A 77 year old male with past medical history of HTN, HLD, prediabetes, obesity, COPD, AAA who initially underwent an CT abdomen pelvis WWO in 6/2013 for evaluation for nephrolithiasis which noted a 1.3 x 2.2 cm cystic structure in the neck of pancreas.

  • <Âé¶¹´«Ã½ÊÓÆµ> ASGE Answers Your Coding Questions

    We understand that for studies we bill for interpretation, the service date is the read date. However, Medicare/Medicaid states for studies like Bravo and capsule endoscopy, it should be the ingestion date. Can you please clarify?

  • <Âé¶¹´«Ã½ÊÓÆµ> Leverage the ASGE Quality Star to Promote Your Unit’s Commitment to Quality

    Now more than ever, demonstrating your GI team's commitment to high-quality, safe, patient-centered care is critical.

  • <Âé¶¹´«Ã½ÊÓÆµ> Digital Health Revolution: Transforming Gastroenterology Care Through Innovation

    As gastroenterologists, we’re no strangers to technological change. From high-definition endoscopes to advanced biologics, innovation has always driven improvements in our field.

  • <Âé¶¹´«Ã½ÊÓÆµ> Optimizing Endoscopy Efficiency Across Settings: Practical Lessons from ASCs and Hospitals

    Efficiency in endoscopic practice is more than just throughput—it’s about delivering safe, timely, and patient-centered care while maintaining the well-being of the healthcare team.

  • <Âé¶¹´«Ã½ÊÓÆµ> ASGE Answers Your Coding Questions

    When a note is signed, is it a legal document and should it not be unlocked to make any changes? Moreover, should any changes be made in an addendum?

  • <Âé¶¹´«Ã½ÊÓÆµ> Improving patient access to colonoscopy/endoscopy by increasing room utilization

    We have noticed that there are often rooms being underutilized for entire or partial days and that the patient backlog of procedures has increased.

  • <Âé¶¹´«Ã½ÊÓÆµ> Case 29: Diarrhea

    A 63-year-old male with a history of hypertension, well-controlled on amlodipine, presents with chronic diarrhea, bloating, and unintentional weight loss of 15 pounds over six months.

  • <Âé¶¹´«Ã½ÊÓÆµ> Silent Epidemic: Addressing Liver Disease as a Major Population Health Challenge

    A Growing and Often Missed BurdenMetabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a major public health threat, one that is often under-recognized due to its silent progression.

  • <Âé¶¹´«Ã½ÊÓÆµ> Quality Counts: Choosing the Right QI Project for Your GI Practice

    Quality improvement (QI) in gastroenterology (GI), is a phrase that is often uttered in conferences, meetings, and on societal websites. It’s a concept that gastroenterologists know is important, but formal training in QI initiatives is not standardized.

  • <Âé¶¹´«Ã½ÊÓÆµ> Rethinking the Role of the Endoscopy Technician: Advancing to the Endoscopy Expert

    The role of the endoscopy technician has traditionally been underrecognized within the gastrointestinal (GI) procedural team. Historically, technicians have received limited formal education, often relying on on-the-job training from senior colleagues.

  • <Âé¶¹´«Ã½ÊÓÆµ> ASGE Answers Your Coding Questions

    Recently we were advised by a representative from the company where we order our breath tests that we should be billing CPT code 91065 twice for each test being performed because the test is inclusive of both hydrogen and methane.

  • <Âé¶¹´«Ã½ÊÓÆµ> 2025 Coding Update for G2211 and Case Study

    It is important to stay up to date on proper and improper utilization of new, deleted and revised codes.  In review of 2025 an important revision occurred for G2211. This HCPCS code was first introduced in January 2024.

  • <Âé¶¹´«Ã½ÊÓÆµ> Private Equity and the GI Physician Shortage: A Solution or a Complication?

    We’re all experiencing the effects of a growing physician shortage. From increased workloads to recruitment challenges and burnout, it’s a multifaceted issue and one I believe deserves candid discussion.

  • <Âé¶¹´«Ã½ÊÓÆµ> ASGE Answers Your Coding Questions

    We are a little confused regarding Modifier KX. Should this modifier be used for only a screening after a positive Cologuard, no biopsies ex: Z12.11/R19.5 G0121/KX, biopsy/polyp removed Z12.11/D12.0/R19.5 45385/KX/PT or both scenarios?